Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Neuronetics (STIM) EBITDA (2017 - 2025)

Neuronetics (STIM) has disclosed EBITDA for 9 consecutive years, with -$7.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 5.27% to -$7.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$37.9 million, a 37.59% decrease, with the full-year FY2024 number at -$34.6 million, down 13.12% from a year prior.
  • EBITDA was -$7.3 million for Q3 2025 at Neuronetics, up from -$8.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$4.4 million in Q4 2023 to a low of -$11.5 million in Q4 2024.
  • A 5-year average of -$8.1 million and a median of -$7.7 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 196.29% in 2021, then skyrocketed 42.71% in 2023.
  • Neuronetics' EBITDA stood at -$6.9 million in 2021, then decreased by 11.84% to -$7.7 million in 2022, then surged by 42.71% to -$4.4 million in 2023, then tumbled by 159.14% to -$11.5 million in 2024, then soared by 36.18% to -$7.3 million in 2025.
  • Per Business Quant, the three most recent readings for STIM's EBITDA are -$7.3 million (Q3 2025), -$8.1 million (Q2 2025), and -$11.0 million (Q1 2025).